CTMX

$4.45-0.33 (-6.90%)

Market ClosedAs of Mar 20, 8:00 PM UTC

CytomX Therapeutics, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.45
Potential Upside
5%
Whystock Fair Value$4.67
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform techn...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$757.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
26.09%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.64

Recent News

Simply Wall St.
Mar 21, 2026

A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results

CytomX Therapeutics (CTMX) is back in focus after reporting early Phase 1 expansion results for its EpCAM-targeting ADC, Varsetatug masetecan, in advanced colorectal cancer, alongside fresh earnings and a sizeable equity raise. See our latest analysis for CytomX Therapeutics. The latest EpCAM ADC data and the US$250.0m follow on equity raise have arrived after a sharp run, with a very large 1 year total shareholder return and a 3 year total shareholder return of 161.76%, even though the 30...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 20, 2026

Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 11 Most Active Small Cap Stocks to Buy. On March 18, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw Jefferies raise its price target to $16 from $8 while maintaining a Buy rating following encouraging Phase 1 data for its lead asset Varseta-M in late-line metastatic colorectal cancer. The analyst highlighted the therapy’s […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Mar 18, 2026

Sector Update: Health Care Stocks Slip Late Afternoon

Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 1.6% and

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 16, 2026

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data

Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.

BEARISH
Negative press. News cycle fixated on risk factors or misses.